Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data

Emily Granger, Ruth H. Keogh, Freddy Frost
ERJ Open Research 2022 8: 00170-2022; DOI: 10.1183/23120541.00170-2022
Emily Granger
1Dept of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emily Granger
  • For correspondence: emily.granger@lshtm.ac.uk
Ruth H. Keogh
1Dept of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Freddy Frost
2Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Freddy Frost
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Flow chart of participant selection. CFRD: cystic fibrosis-related diabetes; CFTR: cystic fibrosis transmembrane conductance regulator; FEV1 %: % predicted forced expiratory volume in 1 s; BMI: body mass index.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Flow of participants in each treatment group by follow-up year, for the n=1196 individuals included in the % predicted forced expiratory volume in 1 s (FEV1 %) analysis.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Estimated effects (and 95% confidence intervals) of insulin use for 1–5 years on % predicted forced expiratory volume in 1 s (FEV1 %) for the whole cohort (“no interaction”) and for people with high, moderate or low FEV1 % at baseline. High, moderate and low FEV1 % were defined as 100, 75 and 40, respectively. IPTW: inverse-probability-of-treatment weighting.

  • FIGURE 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4

    Estimated effects (and 95% confidence intervals) of insulin use for 1–5 years on body mass index (BMI) z-score for the whole cohort (“no interaction”) and for people with high, moderate or low BMI z-score at baseline. High, moderate and low BMI z-score was defined as the 80th, 50th and 20th percentiles of the distribution of BMI z-scores at baseline. IPTW: inverse-probability-of-treatment weighting.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Protocol for the target trial investigating the impact of insulin use on cystic fibrosis-related diabetes (CFRD) outcomes and the corresponding emulated trial using UK Cystic Fibrosis Registry data

    Protocol componentTarget trialEmulated trial
    Eligibility criteriaInclude: Individuals diagnosed with CFRD in the UK aged 12 years and older at time of diagnosis
    Exclude: Individuals who have had an organ transplant or are taking oral corticosteroids or CFTR modulators, prior to CFRD diagnosis
    Include: Individuals observed in the UK CF Registry and labelled with CFRD between 2008 and 2016, meeting criteria in the target trial and who had data for at least one visit within 2 years prior to CFRD diagnosis and at least 1 year of follow-up after diagnosis
    Exclude: As in the target trial. We also exclude people with missing data on baseline confounders, including outcome at baseline, or missing data on infection or pancreatic insufficiency during the follow-up period
    Treatment strategies1) Initiate insulin at CFRD diagnosis and continue to take it throughout follow-up
    2) Do not initiate insulin at CFRD diagnosis and continue not to take insulin throughout follow-up. Individuals in the no insulin group may use other non-insulin treatments for CFRD
    As in the target trial
    Assignment proceduresParticipants will be randomly assigned to a treatment strategy when they are diagnosed with CFRD and will be aware of the strategy to which they have been assignedIn the emulated trial individuals are not randomly assigned to the treatment strategy, which is addressed in the analysis
    Follow-up period1, 2, 3, 4 and 5 years from diagnosisAs in the target trial
    OutcomeWe consider two outcomes:
    1) FEV1 % (obtained using GLI equations)
    2) Body mass index (BMI) z-score
    As in the target trial
    Causal contrasts of interestPer-protocolAs in the target trial
    Analysis planMean difference in outcome between treatment groups at follow-up, adjusted for baseline level. Estimated using a linear regression model for the outcome, with treatment group and baseline measure of the outcome as explanatory variablesConfounding by measured baseline and time-varying covariates is addressed using IPTW of MSMs or G-formula (see section “Statistical analysis”)

    CFRD: cystic fibrosis-related diabetes; CF: cystic fibrosis; CFTR: cystic fibrosis transmembrane conductance regulator; FEV1 %: % predicted forced expiratory volume in 1 s; GLI: Global Lung Function Initiative; BMI: body mass index; IPTW: inverse-probability-of-treatment weighting; MSMs: marginal structural models.

    • TABLE 2

      Summary of characteristics at baseline by insulin use at baseline

      No insulinInsulin
      Subjects n488708
      Female237 (48.6)364 (51.4)
      Age years25.3±12.021.9±9.0
      Genotype#
       High risk395 (80.9)618 (87.3)
       Low risk33 (6.8)14 (2.0)
       Not assigned60 (12.3)76 (10.7)
      FEV1 %64.6±22.064.2±21.4
       Change in previous 12 months¶−1.0±10.6−2.8±10.5
      BMI z-score−0.11±1.29−0.28±1.20
       Change in previous 12 months¶−0.04±0.500.00±0.60
      Pseudomonas aeruginosa infection295 (60.5)468 (66.1)
      Burkholderia cenocepacia complex infection28 (5.7)28 (4.0)
      Staphylococcus aureus infection195 (40.0)302 (42.7)
      Pancreatic enzyme supplements use418 (85.7)637 (89.9)
      Maximum years of post-baseline follow-up
       155 (11.3)79 (11.2)
       258 (11.9)106 (15.0)
       378 (16.0)118 (16.7)
       475 (15.4)81 (11.4)
       5222 (45.5)324 (45.8)

      Continuous variables are summarised using mean±sd and categorical variables are summarised using n (%). FEV1 %: % predicted forced expiratory volume in 1 s; BMI: body mass index. #: genotype risk as described by Mckone et al. [34]. ¶: changes in FEV1 % and BMI are the changes from previous visit (i.e. difference between measures 2 years prior to cystic fibrosis-related diabetes diagnosis and 1 year prior to CFRD diagnosis).

      Supplementary Materials

      • Figures
      • Tables
      • Supplementary Material

        Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

        Supplementary material 00170-2022.SUPPLEMENT

      PreviousNext
      Back to top
      Vol 8 Issue 4 Table of Contents
      ERJ Open Research: 8 (4)
      • Table of Contents
      • Index by author
      Email

      Thank you for your interest in spreading the word on European Respiratory Society .

      NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

      Enter multiple addresses on separate lines or separate them with commas.
      The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data
      (Your Name) has sent you a message from European Respiratory Society
      (Your Name) thought you would like to see the European Respiratory Society web site.
      CAPTCHA
      This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
      Print
      Citation Tools
      The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data
      Emily Granger, Ruth H. Keogh, Freddy Frost
      ERJ Open Research Oct 2022, 8 (4) 00170-2022; DOI: 10.1183/23120541.00170-2022

      Citation Manager Formats

      • BibTeX
      • Bookends
      • EasyBib
      • EndNote (tagged)
      • EndNote 8 (xml)
      • Medlars
      • Mendeley
      • Papers
      • RefWorks Tagged
      • Ref Manager
      • RIS
      • Zotero
      Share
      The long-term effects of insulin use in incident cystic fibrosis-related diabetes: a target trial emulated using longitudinal national registry data
      Emily Granger, Ruth H. Keogh, Freddy Frost
      ERJ Open Research Oct 2022, 8 (4) 00170-2022; DOI: 10.1183/23120541.00170-2022
      del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
      Full Text (PDF)

      Jump To

      • Article
        • Abstract
        • Abstract
        • Introduction
        • Methods
        • Results
        • Discussion
        • Supplementary material
        • Footnotes
        • References
      • Figures & Data
      • Info & Metrics
      • PDF

      Subjects

      • CF and non-CF bronchiectasis
      • Tweet Widget
      • Facebook Like
      • Google Plus One

      More in this TOC Section

      Original research articles

      • Bacterial DNA amplifies neutrophilic inflammation in IL-17-exposed airways
      • PERSPIRE: a cohort study
      • Ipratropium bromide in EILO
      Show more Original research articles

      Cystic fibrosis

      • Nasal epithelial cell FRAP predicts CF therapy response
      • Diagnostic agreement in cystic fibrosis
      • Long-term effectiveness of dual CFTR modulator treatment
      Show more Cystic fibrosis

      Related Articles

      Navigate

      • Home
      • Current issue
      • Archive

      About ERJ Open Research

      • Editorial board
      • Journal information
      • Press
      • Permissions and reprints
      • Advertising

      The European Respiratory Society

      • Society home
      • myERS
      • Privacy policy
      • Accessibility

      ERS publications

      • European Respiratory Journal
      • ERJ Open Research
      • European Respiratory Review
      • Breathe
      • ERS books online
      • ERS Bookshop

      Help

      • Feedback

      For authors

      • Instructions for authors
      • Publication ethics and malpractice
      • Submit a manuscript

      For readers

      • Alerts
      • Subjects
      • RSS

      Subscriptions

      • Accessing the ERS publications

      Contact us

      European Respiratory Society
      442 Glossop Road
      Sheffield S10 2PX
      United Kingdom
      Tel: +44 114 2672860
      Email: journals@ersnet.org

      ISSN

      Online ISSN: 2312-0541

      Copyright © 2023 by the European Respiratory Society